Ask your AI about this

Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:

Connect your AI · Plans and the 7-day free trial (card required)

Buying and selling by quarter

Dollars bought and sold on the open market over the last two years.

$0$1.0M$2.0M$3.0M$4.0MQ4 2024 · Bought: $0Q4 2024 · Sold: $91,627Q4 2024Q1 2025 · Bought: $0Q1 2025 · Sold: $140,792Q1 2025Q2 2025 · Bought: $0Q2 2025 · Sold: $77,547Q2 2025Q3 2025 · Bought: $0Q3 2025 · Sold: $128,909Q3 2025Q4 2025 · Bought: $0Q4 2025 · Sold: $251,959Q4 2025Q1 2026 · Bought: $0Q1 2026 · Sold: $834,977Q1 2026Q2 2026 · Bought: $0Q2 2026 · Sold: $1,865,134Q2 2026Q3 2026 · Bought: $0Q3 2026 · Sold: $3,867,212Q3 2026Q4 2026 · Bought: $0Q4 2026 · Sold: $1,949,900Q4 2026

Bought Sold

By trade date, using the shares and price reported for each trade. Stock grants, option exercises and shares withheld for tax are left out.

Roles

The companies where this person reports as an insider, and their position at each, most recent first.

Roles by company
CompanyRoleLast filed
TXG
10x Genomics, Inc.
Chief Executive Officer, DirectorNov 13, 2026

Roles come from the filings themselves and can change over time.

Latest open-market trades

Purchases and sales at every company, most recent filing first.

Latest insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.Filing
Nov 10, 2026TXG
10x Genomics, Inc.
Sale31,000$62.90$1.9M-8.1%Form 4 ↗
Sep 22, 2026TXG
10x Genomics, Inc.
Sale1,000$78.23$78.2K-25.4%Form 4 ↗
Sep 22, 2026TXG
10x Genomics, Inc.
Sale2,000$79.62$159.2K-25.4%Form 4 ↗
Sep 22, 2026TXG
10x Genomics, Inc.
Sale9,300$80.90$752.4K-25.4%Form 4 ↗
Sep 22, 2026TXG
10x Genomics, Inc.
Sale9,900$81.83$810.1K-25.4%Form 4 ↗
Sep 22, 2026TXG
10x Genomics, Inc.
Sale2,800$82.37$230.6K-25.4%Form 4 ↗
Aug 26, 2026TXG
10x Genomics, Inc.
Sale6,494$63.98$415.5K-7.9%Form 4 ↗
Aug 26, 2026TXG
10x Genomics, Inc.
Sale3,500$63.02$220.6K-7.9%Form 4 ↗
Aug 26, 2026TXG
10x Genomics, Inc.
Sale492$64.75$31.9K-7.9%Form 4 ↗
Aug 24, 2026TXG
10x Genomics, Inc.
Sale18,545$63.02$1.2M-7.6%Form 4 ↗
Jun 22, 2026TXG
10x Genomics, Inc.
Sale8,527$33.29$283.9K+75.3%Form 4 ↗
Jun 22, 2026TXG
10x Genomics, Inc.
Sale9,991$34.28$342.5K+75.3%Form 4 ↗
Jun 22, 2026TXG
10x Genomics, Inc.
Sale9,821$35.32$346.9K+75.3%Form 4 ↗
Jun 22, 2026TXG
10x Genomics, Inc.
Sale1,661$36.16$60.1K+75.3%Form 4 ↗
May 26, 2026TXG
10x Genomics, Inc.
Sale10,718$24.71$264.8K+135.8%Form 4 ↗
May 22, 2026TXG
10x Genomics, Inc.
Sale18,175$24.44$444.2K+144.6%Form 4 ↗
Apr 14, 2026TXG
10x Genomics, Inc.
Sale5,000$24.56$122.8K+126.0%Form 4 ↗
Mar 24, 2026TXG
10x Genomics, Inc.
Sale5,000$19.52$97.6K+178.2%Form 4 ↗
Mar 23, 2026TXG
10x Genomics, Inc.
Sale10,000$19.13$191.3K+188.9%Form 4 ↗
Mar 2, 2026TXG
10x Genomics, Inc.
Sale14,292$22.67$324.0K+141.6%Form 4 ↗
Mar 2, 2026TXG
10x Genomics, Inc.
Sale1,860$23.18$43.1K+141.6%Form 4 ↗
Feb 23, 2026TXG
10x Genomics, Inc.
Sale9,632$18.58$179.0K+197.5%Form 4 ↗
Nov 24, 2025TXG
10x Genomics, Inc.
Sale13,261$19.00$252.0K+176.3%Form 4 ↗
Aug 22, 2025TXG
10x Genomics, Inc.
Sale9,348$13.79$128.9K+290.0%Form 4 ↗
May 22, 2025TXG
10x Genomics, Inc.
Sale9,343$8.30$77.5K+552.0%Form 4 ↗
Feb 28, 2025TXG
10x Genomics, Inc.
Sale7,942$10.63$84.4K+417.4%Form 4 ↗
Feb 24, 2025TXG
10x Genomics, Inc.
Sale5,092$11.07$56.4K+389.1%Form 4 ↗
Nov 22, 2024TXG
10x Genomics, Inc.
Sale6,693$13.69$91.6K+280.0%Form 4 ↗

Each row links to its Form 4. Since trade compares the stock’s move from the close on the trade date (or the next trading day) to its latest close with the S&P 500 over the same days, adjusted for splits and excluding dividends. It describes the stock, not what the trader made: we don’t know their purchase price, position size or later sales. A dash means the trade isn’t matched to a listed stock, or there is no closing price after it yet.

When several people report on the same filing, we list it under the first one named, so trades by someone usually listed second may be missing here. Information, not investment advice: see the disclaimer.